Aedes aegypti is the principal vector of Zika virus and several other medically-important arboviruses, such as chikungunya and dengue. Presently, efforts to control mosquito-borne diseases rely heavily on the use of insecticides targeting the nervous system (e.g., pyrethroids) to reduce mosquito populations. However, the emergence of insecticide resistance in mosquitoes is reducing the efficacy of these control agents. Thus, new insecticides with novel mechanisms of action are needed. We have previously demonstrated that 1) inward-rectifier potassium (Kir) channels perform fundamental roles in mosquito excretion and reproduction, and 2) small-molecule inhibitors of mosquito Kir channels elicit toxic effects on mosquitoes. Thus, Kir channels represent useful molecular targets for developing insecticides with novel mechanisms of action. The proposed work aims to develop small molecule inhibitors of Kir channels into resistance-breaking mosquitocides that would have nominal effects on humans and honey bees (Apis mellifera).
Aim 1 will use leading-edge drug discovery approaches to develop analogs of 3 inhibitors of the Ae. aegypti Kir1 channel (AeKir1) that exhibit topical toxicity on mosquitoes. We will identify analogs that potently inhibit AeKir1, but do not inhibit a panel of human Kir channels and the honey bee Kir1 channel in vitro.
Aim 2 will utilize in vivo toxicology assays in 1) pyrethroid-susceptible and pyrethroid-resistant adult female Ae. aegypti and 2) adult honey bees to evaluate the toxicity, resistance-breaking potential, and species- selectivity of the analogs. Moreover, the analogs will be tested in vitro with radioligand binding assays to assess their interactions with high-priority mammalian off-targets and thereby their potential human toxicity. Taken together, the results from the two aims will yield a diverse collection of potent and selective AeKir1 inhibitor analogs and identify those that exhibit the greatest potential for development into novel, safe mosquitocides for controlling the primary vector of Zika, dengue, and chikungunya viruses.

Public Health Relevance

The mosquito Aedes aegypti is the primary vector of Zika virus, an arbovirus that was introduced to the Western hemisphere in 2015 and is suspected in alarmingly high numbers of cases of microcephaly and Guillain-Barr syndrome. Ae. aegypti is also the primary vector of chikungunya, dengue, and yellow fevers, which are emerging and re-emerging diseases of global concern. Insecticides are used to control the spread of mosquito-borne diseases, but the emergence of resistance in mosquitoes is reducing the efficacy of conventional control agents. The present proposal aims to develop new chemicals for controlling insecticide-resistant mosquitoes that are safe to humans and beneficial insects (e.g., honey bees).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI128418-01A1
Application #
9386127
Study Section
Vector Biology Study Section (VB)
Program Officer
Costero-Saint Denis, Adriana
Project Start
2017-06-01
Project End
2019-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
1
Fiscal Year
2017
Total Cost
$255,820
Indirect Cost
$41,188
Name
Ohio State University
Department
Type
Organized Research Units
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Piermarini, Peter M; Inocente, Edna Alfaro; Acosta, Nuris et al. (2018) Inward rectifier potassium (Kir) channels in the soybean aphid Aphis glycines: Functional characterization, pharmacology, and toxicology. J Insect Physiol 110:57-65